Trial | NCT01368419  Report issue

Title

Continuous Endostar Infusion Combined With Radiotherapy in Esophageal Cancer Patients
Phase II Study of Continuous Endostar Infusion Combined With Radiotherapy in Esophageal Cancer Patients

  • Phase

    Phase 2

  • Study Type

    Interventional

  • Status

    Unknown status

  • Intervention/Treatment

    endostatin ...

  • Study Participants

    40
This study is to explore the clinical efficacy of continuous Endostar infusion combined with radiotherapy in esophageal cancer patients.
Study Started
May 31
2011
Primary Completion
May 31
2013
Anticipated
Study Completion
May 31
2013
Anticipated
Last Update
Apr 24
2013
Estimate

Drug Endostar

75mg Endostar in 235mL normal saline, 24h continuous infusion, 6 weeks

Radiation Radiotherapy

6～15MV X-ray, 2Gy/time，5times/week，6 weeks

Treatment Experimental

Criteria 

Inclusion Criteria:

Histological or cytological diagnosis of previously untreated stage I-III esophageal cancer
Measurable disease according to RECIST criteria
ECOG Performance Status 0-1
The length of esophageal carcinoma ≤ 10 cm
Hematologic function: WBC ≥ 4.0×109/L, PLT ≥ 80×109/L, Hb ≥ 90g/L
Renal function: Cr ≤ 2.0×UNL
Hepatic function: BIL ≤ 2.0×UNL, ALT/AST ≤ 5.0×UNL

Exclusion Criteria:

Pregnant or lactating women
Evidence of bleeding diathesis, serious infection
Serious cardiovascular disease (congestive heart failure, uncontrollable arrhythmia, unstable angina, myocardial infarction, serious heart valve disease, resistant hypertension)
Uncontrollable mental and nervous disorders
No Results Posted